Voting Rights and Shares Capital of the Company
Nanobiotix (NBTX) has released its latest voting rights and share capital statement as of March 31, 2025. The company reported 47,426,851 shares outstanding, with 49,193,374 theoretical voting rights and 49,171,256 exercisable voting rights. This disclosure complies with French regulatory requirements, including the French Commercial Code and Financial Markets Authority regulations.
Nanobiotix (NBTX) ha pubblicato il suo ultimo rendiconto sui diritti di voto e sul capitale sociale al 31 marzo 2025. La società ha riportato 47.426.851 azioni in circolazione, con 49.193.374 diritti di voto teorici e 49.171.256 diritti di voto esercitabili. Questa comunicazione è conforme alle normative francesi, inclusi il Codice Commerciale francese e le disposizioni dell’Autorità dei Mercati Finanziari.
Nanobiotix (NBTX) ha publicado su último informe sobre derechos de voto y capital social a fecha del 31 de marzo de 2025. La compañía reportó 47.426.851 acciones en circulación, con 49.193.374 derechos de voto teóricos y 49.171.256 derechos de voto ejercibles. Esta divulgación cumple con los requisitos regulatorios franceses, incluyendo el Código de Comercio francés y las regulaciones de la Autoridad de Mercados Financieros.
Nanobiotix (NBTX)는 2025년 3월 31일 기준 최신 의결권 및 자본금 현황을 발표했습니다. 회사는 47,426,851주 발행 주식과 49,193,374 이론적 의결권, 그리고 49,171,256 행사 가능한 의결권을 보고했습니다. 이 공시는 프랑스 상법 및 금융시장청 규정을 포함한 프랑스 규제 요건을 준수합니다.
Nanobiotix (NBTX) a publié sa dernière déclaration relative aux droits de vote et au capital social au 31 mars 2025. La société a déclaré 47 426 851 actions en circulation, avec 49 193 374 droits de vote théoriques et 49 171 256 droits de vote exerçables. Cette divulgation est conforme aux exigences réglementaires françaises, notamment le Code de commerce français et les règlements de l’Autorité des marchés financiers.
Nanobiotix (NBTX) hat seine aktuelle Erklärung zu Stimmrechten und Aktienkapital zum 31. März 2025 veröffentlicht. Das Unternehmen meldete 47.426.851 ausstehende Aktien mit 49.193.374 theoretischen Stimmrechten und 49.171.256 ausübbaren Stimmrechten. Diese Offenlegung entspricht den französischen regulatorischen Anforderungen, einschließlich des französischen Handelsgesetzbuchs und der Vorschriften der Finanzmarktaufsicht.
- None.
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, April 14, 2025 (GLOBE NEWSWIRE) --
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| March 31, 2025 | 47,426,851 | 49,193,374 | 49,171,256 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com | |
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachment
FAQ
What is the current number of outstanding shares for Nanobiotix (NBTX) as of March 2025?
How many voting rights does NBTX stock have as of March 2025?
What is the difference between theoretical and exercisable voting rights for NBTX?
On which exchanges is Nanobiotix (NBTX) stock traded?
